<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="741">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>12/09/2005</approvaldate>
  <nctid>NCT00163852</nctid>
  <trial_identification>
    <studytitle>Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis</studytitle>
    <scientifictitle>Salt Replacement for Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>14/04</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Normal saline IV, salt tablets

Treatment: drugs: Normal saline IV, salt tablets


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary outcome measures: (Day1, D4, D10)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>PaCO2 (performed at same time of day as admission ABGs)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Acid-base status (Stinebaugh and Austin, ABGs)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Serum chloride</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Overnight oximetry (% night SpO2&lt;90%) and PtcCO2 (rise in CO2 overnight)</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary outcome measures: (Day1, D4, D10)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum albumin, sodium</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Body mass index (BMI)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Spirometry (D1, D10)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Headache scale</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Epworth sleepiness scale</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Wrist actigraphy (circadian rhythm and daytime activity level)(D1-10)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Urinary chloride, potassium, sodium, pH, osmolality</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Baseline ABGs as stable outpatient (within 3 months, pre or post admission)</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adult cystic fibrosis patient

          -  Admission with acute exacerbation (criteria- fall in FEV1 &gt; 10% from best in last
             12/12, change in sputum volume and colour, new pulmonary infiltrate)

          -  PaCO2 &gt; 45 mmHg on admission

          -  Primary metabolic alkalosis (acid-base diagram of Stinebaugh and Austin)

          -  Serum chloride (Cl) = 98 mmol/L

          -  Serum albumin (alb) = 25 mmol/L</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Concurrent diuretic therapy Concurrent glucocorticoid therapy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred - Melbourne</hospital>
    <postcode>3181 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Bayside Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Monash University</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cystic Fibrosis Federation Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Adult cystic fibrosis (CF) patients admitted with an acute infection complicated by acid-base
      disturbance and decreased ventilation will be studied.

      They will receive salt replacement to correct the acid-base disturbance and possibly their
      ventilation.

      Assessment of symptoms (questionnaire), acid-base and electrolyte status (blood and urine
      tests) ventilation (overnight oxygen and carbon dioxide monitoring non-invasively) and
      sleep-wake pattern (actigraphy) will be carried out.

      Study hypothesis: Acute volume and electrolyte replacement corrects hypochloremic hypovolemic
      metabolic alkalosis and compensatory hypoventilation/ hypercapnia in acute exacerbations of
      cystic fibrosis.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00163852</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Matthew T Naughton, MBBS, MD</name>
      <address>The Alfred</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Alan C Young, MBBS, FRACP</name>
      <address />
      <phone>613 9276 2000</phone>
      <fax />
      <email>alan.young@med.monash.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>